Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction

Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction

Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP), and the addition of ezetimibe to statins further reduces LDL-C and hsCRP. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a potentially important pathogenic factor participating in the pro...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2017-11, Vol.14 (5), p.4942-4950
Main Authors: Ren, Yizhi, Zhu, Hao, Fan, Zhongguo, Gao, Yali, Tian, Nailiang
Format: Article
Language:eng
Subjects:
AMI
Analysis
Atherosclerosis
Biomarkers
Blood cholesterol
Cardiovascular disease
Care and treatment
Cholesterol
Comparative analysis
Development and progression
Dosage and administration
Ezetimibe
Family medical history
Heart attack
Heart attacks
Hospitals
hsCRP
LDL-C
Lipids
Low density lipoprotein
Lp-PLA2
Proteins
Rosuvastatin
Software
Statins
Studies
Testing
Triglycerides
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP), and the addition of ezetimibe to statins further reduces LDL-C and hsCRP. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a potentially important pathogenic factor participating in the progression of atherosclerosis. The aim of current study was to investigate how the addition of ezetimibe to rosuvastatin treatment affects reductions in LDL-C, hsCRP and Lp-PLA2 in patients with acute myocardial infarction (AMI). A total of 135 patients were enrolled in the study within 24 h of AMI, and were randomized to receive 10 mg rosuvastatin or 10 mg rosuvastatin plus 10 mg ezetimibe daily. HsCRP, Lp-PLA2, total cholesterol (TC), triglycerides (TG), LDL-C and high-density lipoprotein cholesterol (HDL-C) were determined at baseline and after 1, 3, 6 and 12 months of treatment. The addition of ezetimibe to rosuvastatin led to greater reduction of LDL-C compared with rosuvastatin monotherapy (from 3.00 to 1.19 mmol/l vs. 2.93 to 1.49 mmol/l, respectively; P
ISSN:1792-0981
1792-1015